Rathi Sandeep, Kazerounian Shiva, Banwait Kuldip, Schulz Stephanie, Waldman Scott A, Rattan Satish
Department of Medicine, Division of Gastroenterology and Hepatology, Jefferson Medical College, Thomas Jefferson University, 1025 Walnut Street, Room no. 901 College, Philadelphia, PA 19107, USA.
J Pharmacol Exp Ther. 2003 May;305(2):615-24. doi: 10.1124/jpet.102.048462. Epub 2003 Feb 11.
The purpose of the present study was to characterize different beta-adrenoceptors (beta-ARs) and determine their role in the spontaneously tonic smooth muscle of the internal anal sphincter (IAS). The beta-AR subtypes in the opossum IAS were investigated by functional in vitro, radioligand binding, Western blot, and reverse transcription-polymerase chain reaction (RT-PCR) studies. ZD 7114 [(S)-4-[2-hydroxy-3-phenoxypropylaminoethoxy]-N-(2-methoxyethyl)phenoxyacetamide], a selective beta(3)-AR agonist, caused a potent and concentration-dependent relaxation of the IAS smooth muscle that was antagonized by the beta(3)-AR antagonist SR 59230A [1-(2-ethylphenoxy)-3-[[(1S)-1,2,3,4-tetrahydro-1-naphthalenyl]amino]-(2S)-2-propanol hydrochloride]. Conversely, the IAS smooth muscle relaxation caused by beta(1)- and beta(2)-AR agonists (xamoterol and procaterol, respectively) was selectively antagonized by their respective antagonists CGP 20712 [(+/-)-2-hydroxy-5-[2-[[2-hydroxy-3-[4-[1-methyl-4-(trifluoromethyl)-1H-imidazol-2-yl]phenoxy]propyl]amino]ethoxy]-benzamide methanesulfonate salt] and ICI 118551. Saturation binding of [(125)I]iodocyanopindolol to beta-AR subtypes revealed the presence of a high-affinity site (K(d1) = 96.4 +/- 8.7 pM; B(max1) = 12.5 +/- 0.6 fmol/mg protein) and a low-affinity site (K(d2) = 1.96 +/- 1.7 nM; B(max2) = 58.7 +/- 4.3 fmol/mg protein). Competition binding with selective beta-AR antagonists revealed that the high-affinity site correspond to beta(1)/beta(2)-AR and the low affinity site to beta(3)-AR. Receptor binding data suggest the predominant presence of beta(3)-AR over beta(1)/beta(2)-AR. Western blot studies identified beta(1)-, beta(2)-, and beta(3)-AR subtypes. The presence of beta(1)-, beta(2)-, and beta(3)-ARs was further demonstrated by mRNA analysis using RT-PCR. The studies demonstrate a comprehensive functional and molecular characterization of beta(1)-, beta(2)-, and beta(3)-ARs in IAS smooth muscle. These studies may have important implications in anorectal and other gastrointestinal motility disorders.
本研究的目的是对不同的β-肾上腺素能受体(β-ARs)进行表征,并确定它们在肛门内括约肌(IAS)自发性紧张性平滑肌中的作用。通过体外功能研究、放射性配体结合研究、蛋白质印迹法和逆转录-聚合酶链反应(RT-PCR)研究,对负鼠IAS中的β-AR亚型进行了研究。ZD 7114 [(S)-4-[2-羟基-3-苯氧基丙基氨基乙氧基]-N-(2-甲氧基乙基)苯氧基乙酰胺],一种选择性β(3)-AR激动剂,可引起IAS平滑肌有效且浓度依赖性的舒张,该舒张作用被β(3)-AR拮抗剂SR 59230A [1-(2-乙基苯氧基)-3-[[(1S)-1,2,3,4-四氢-1-萘基]氨基] -(2S)-2-丙醇盐酸盐]拮抗。相反,β(1)-和β(2)-AR激动剂(分别为xamoterol和丙卡特罗)引起的IAS平滑肌舒张被它们各自的拮抗剂CGP 20712 [(±)-2-羟基-5-[2-[[2-羟基-3-[4-[1-甲基-4-(三氟甲基)-1H-咪唑-2-基]苯氧基]丙基]氨基]乙氧基]-苯甲酰胺甲磺酸盐]和ICI 118551选择性拮抗。[(125)I]碘氰吲哚洛尔与β-AR亚型的饱和结合显示存在一个高亲和力位点(K(d1) = 96.4 ± 8.7 pM;B(max1) = 12.5 ± 0.6 fmol/mg蛋白质)和一个低亲和力位点(K(d2) = 1.96 ± 1.7 nM;B(max2) = 58.7 ± 4.3 fmol/mg蛋白质)。与选择性β-AR拮抗剂的竞争结合表明,高亲和力位点对应于β(1)/β(2)-AR,低亲和力位点对应于β(3)-AR。受体结合数据表明β(3)-AR比β(1)/β(2)-AR占优势。蛋白质印迹研究鉴定出了β(1)-、β(2)-和β(3)-AR亚型。使用RT-PCR进行的mRNA分析进一步证实了β(1)-、β(2)-和β(3)-AR的存在。这些研究展示了IAS平滑肌中β(1)-、β(2)-和β(3)-AR的全面功能和分子特征。这些研究可能对肛肠及其他胃肠动力障碍具有重要意义。